skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hi there, I noticed a recent answer where you recommended COV and GUD for a growth and balanced healthcare name. I know it may be best to split a position in two and own both names, but if you had to buy just one which would it be - for short term (1-2 years) or long term (5-10 years)? Thanks!
Read Answer Asked by Michael on December 07, 2017
Q: Hi Peter,

I've been watching this closely since it was first recommended. It's now back to the low $4's and is looking quite attractive.

Before I pull the trigger and jump in, can you remind me of the positive attributes and potential long term earnings potential? If you were to give me a best 3-5 year price target 'guesstimate' assuming things work out with the company, what might that look like?
Read Answer Asked by Michael on December 07, 2017
Q: I have a question about two companies.

11.6% of XX shares were acquired by Campbell at 39.5 cents. The stock was halted and it dropped after the halt was removed to around 33 cents. Do you think there is something cooking or it is just pure speculation. Would you recommend buying If already owned.

CHH dropped a lot due to CEO resignation and the shares dropped. I already had some shares at 63 cents and I bought more at 53. Is this a good company for one year time frame. Thanks
Read Answer Asked by Imtiaz on December 06, 2017
Q: Greetings 5i,

VRX seems to have rallied since it reported. Mgt looks to be doing a good job in reducing debt and providing transparency. They also offered notes I believe mid November reducing near term debt. I know you are cautious re: VRX however what additionally would be needed to endorse this company? It seems to be racing away as we sit and hope for more improvements.

Cheers!
Read Answer Asked by Duane on December 04, 2017
Q: During the merger period in the Canadian Cannabis Industry, who do you see as the potential winners?
Read Answer Asked by Van on December 01, 2017
Q: Hello Peter and Ryan,
Cannimed has provided the following press release
http://www.businesswire.com/news/home/20171130006170/en/Actions-Words-Aurora-CEO%E2%80%99s-Actions-Reveal-Aurora
which basically illustrates insider selling by Aurora executives on November 28, 2017 while Aurora is in the midst of a takeover of Cannimed.
How is this recent information on insider selling obtained? I am thinking of adding to Savaria Corp giving it total of 5 percent weight and Knight to 7 percent given its recent weakness. Any comments please. Thanks again
Read Answer Asked by umedali on December 01, 2017
Q: You had responded to a previous member question about Neptune Tech waiting for its Investor communications on Nov 28th. I see it has sold the Krill Oil business and is now into cannabis derivative products. The current p/e is stated as 5.5 x and there was quite a bit of insider buying (albeit at lower prices). Has your opinion changed as to whether this would be a good speculative purchase for me?
Thanks,
Brian
Read Answer Asked by Brian on December 01, 2017
Q: Hello Folks:
Could you please give me your view on Merck and Company (which along with Smith- Kline) has had problems executing new drugs (eg. lung cancer medications) in their pipelines. I also have previously owned Gilead, whose new HIV drug was reduced in value because of government pricing restrictions. My other health care equities are Johnson and Johnson and Knight Therapeutics. Do you think there are better health industry options (with decent dividends and growth potential) in the U.S. other than companies such as Merck, Gilead etc. or should one look to another sector.
Thanks for everything
brian
Read Answer Asked by Brian on November 30, 2017
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!